MIX • CALCULATE • UNDERSTAND

RECONSTITUTION EDUCATION

Goal-organized reference information for concentration math, common research-vial reconstitution examples, and study-context notes.

Important: This page is educational reference material, not individualized dosing or medical advice. Reconstitution does not make an unapproved product safe or approved for human use. For FDA-approved prescription products, use the manufacturer-supplied formulation/diluent and follow the prescriber and official labeling. “Reference” doses below reflect the submitted educational guide or research context and are not instructions to self-administer.

Common concentration examples

2 mg + 2 mL = 1 mg/mL
5 mg + 2 mL = 2.5 mg/mL
10 mg + 2 mL = 5 mg/mL

U-100 syringe volume

1 unit = 0.01 mL
10 units = 0.1 mL
100 units = 1 mL

Storage

Storage and beyond-use time are product-specific. Follow supplier/manufacturer instructions. Refrigeration and light protection are common for many reconstituted peptides, but a universal “2–4 week” rule is not reliable.

Sterility

Use aseptic technique and never use a vial that appears contaminated, damaged, cloudy when it should be clear, or otherwise compromised.

FAT LOSS & WEIGHT MANAGEMENT

Semaglutide

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: 0.25 mg weekly → titrated per approved product labeling
Cycle / context: Long-term when prescribed
Research note: GLP-1 receptor agonist. Commercial FDA-approved semaglutide products are supplied in approved dosage forms; compounded/research-vial practices are not interchangeable with product labeling.

Tirzepatide

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: 2.5 mg weekly → titrated per approved product labeling
Cycle / context: Long-term when prescribed
Research note: Dual GIP/GLP-1 receptor agonist. FDA-approved products exist for diabetes and chronic weight management; follow the specific approved product instructions.

Retatrutide

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: Research reference: 1–12 mg weekly ranges have been studied
Cycle / context: Investigational
Research note: Triple GIP/GLP-1/glucagon receptor agonist; investigational, not an FDA-approved medicine as of this guide.

Survodutide

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: Research reference: titration used in clinical trials
Cycle / context: Investigational
Research note: Dual GLP-1/glucagon receptor agonist in clinical development.

Mazdutide

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Research reference: 3–6 mg weekly
Cycle / context: Investigational / region-specific
Research note: Dual GLP-1/glucagon receptor agonist; regulatory status varies by country.

AOD-9604

Reconstitution reference: 2 mL BAC water / 2 mg vial
Dose / study reference: Reference: 250–500 mcg daily
Cycle / context: 8 weeks on / 8 weeks off (reference)
Research note: Growth-hormone fragment studied for metabolic effects; not an FDA-approved weight-loss drug.

5-Amino-1MQ

Reconstitution reference: 3 mL BAC water / 10 mg vial
Dose / study reference: Reference: 150–300 mcg daily
Cycle / context: 8–12 weeks (reference)
Research note: Experimental NNMT inhibitor; human safety/efficacy data are limited.

MOTS-C

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 5–20 mg weekly
Cycle / context: 8–12 weeks (reference)
Research note: Mitochondrial-derived peptide studied in metabolism and cellular signaling; investigational.

SLU-PP-332

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: No established human dose
Cycle / context: Preclinical research
Research note: Experimental ERR agonist studied primarily in preclinical models; it is not a GLP-1 receptor agonist.

Cagrilintide

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Research reference: 0.6–2.4 mg weekly
Cycle / context: Investigational
Research note: Long-acting amylin analog in clinical development.

L-Carnitine

Reconstitution reference: Product-specific
Dose / study reference: Dose/route are product- and indication-specific
Cycle / context: Varies
Research note: A nutrient/medication rather than a peptide; injectable use should follow labeled/prescribed formulation.

Melanotan II

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: No established approved human dose
Cycle / context: Experimental
Research note: Unapproved melanocortin analog; safety concerns and product-quality variability warrant caution.

MUSCLE GROWTH & GH-AXIS RESEARCH

HGH 191AA (somatropin)

Reconstitution reference: Product-specific
Dose / study reference: Prescription dosing is indication-specific
Cycle / context: Medical supervision
Research note: Prescription growth hormone; not appropriate to treat as a generic research-vial protocol.

IGF-1 LR3

Reconstitution reference: 1 mL BAC water / 1 mg vial
Dose / study reference: No established approved human dose
Cycle / context: Experimental
Research note: Long-acting IGF analog; investigational.

MGF

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: No established approved human dose
Cycle / context: Experimental
Research note: IGF-1 splice-variant research compound.

CJC-1295 with DAC

Reconstitution reference: 2 mL BAC water / 2 mg vial
Dose / study reference: Reference: 1–2 mg twice weekly
Cycle / context: Research reference
Research note: Long-acting GHRH analog; investigational.

GHRP-6

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 100–300 mcg, 2–3× daily
Cycle / context: Research reference
Research note: Growth-hormone secretagogue; investigational.

GHRP-2

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 100–300 mcg, 2–3× daily
Cycle / context: Research reference
Research note: Growth-hormone secretagogue; investigational.

Hexarelin

Reconstitution reference: 2 mL BAC water / 2 mg vial
Dose / study reference: Reference: 100–200 mcg, 2–3× daily
Cycle / context: Short research cycles
Research note: Potent GH secretagogue with desensitization concerns.

Ipamorelin

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 100–300 mcg, 2–3× daily
Cycle / context: Research reference
Research note: Selective GH secretagogue; investigational.

Tesamorelin

Reconstitution reference: Use manufacturer-supplied diluent/instructions for approved product
Dose / study reference: Approved prescription regimen is product-specific
Cycle / context: Medical supervision
Research note: FDA-approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy; not approved for general weight loss.

HCG

Reconstitution reference: Use labeled/prescribed diluent
Dose / study reference: Prescription dosing is indication-specific
Cycle / context: Medical supervision
Research note: Prescription hormone, not a peptide research protocol.

HMG

Reconstitution reference: Use labeled/prescribed diluent
Dose / study reference: Prescription dosing is indication-specific
Cycle / context: Medical supervision
Research note: Prescription gonadotropin used in fertility care.

Gonadorelin

Reconstitution reference: Product-specific
Dose / study reference: Prescription/research dosing varies
Cycle / context: Medical supervision
Research note: GnRH analog; use depends on indication and formulation.

INJURY HEALING & RECOVERY

BPC-157

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 250–500 mcg daily
Cycle / context: 4–6 weeks (reference)
Research note: Experimental gastric-derived peptide fragment; human clinical evidence is limited. It is not brain-derived neurotrophic factor.

TB-500 / thymosin-beta-4 related

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 2–2.5 mg twice weekly
Cycle / context: 4–8 weeks (reference)
Research note: Synthetic products sold as TB-500 are investigational; do not equate them automatically with endogenous thymosin beta-4.

GHK-Cu

Reconstitution reference: 10 mL BAC water / 50–100 mg vial (reference)
Dose / study reference: Reference: 1–3 mg daily
Cycle / context: 4–12 weeks (reference)
Research note: Copper-binding tripeptide studied in skin/tissue biology; route-specific evidence differs.

Tri-Heal (BPC-157 + TB-500 + KPV)

Reconstitution reference: 5 mL BAC water / vial
Dose / study reference: Reference depends on exact vial composition
Cycle / context: 4–8 weeks (reference)
Research note: Combination research product; concentration must be calculated from the actual labeled amounts.

ARA-290 / cibinetide

Reconstitution reference: 3.2 mL BAC water / 16 mg vial
Dose / study reference: Reference: 2–4 mg twice weekly
Cycle / context: 4–8 weeks (reference)
Research note: Non-erythropoietic EPO-derived peptide studied for tissue-protective signaling.

LL-37

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 200–500 mcg daily
Cycle / context: 2–4 weeks (reference)
Research note: Human cathelicidin antimicrobial peptide; investigational systemic use.

PE-22-28

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: No established approved human dose
Cycle / context: Experimental
Research note: Experimental neuroactive peptide; evidence is limited.

SS-31 / elamipretide

Reconstitution reference: 3 mL BAC water / 10 mg vial
Dose / study reference: Research reference: 0.25–1 mg daily
Cycle / context: Research reference
Research note: Mitochondria-targeted peptide studied clinically; regulatory status should be checked.

Glutathione

Reconstitution reference: Product-specific
Dose / study reference: Route/dose are formulation-specific
Cycle / context: Varies
Research note: Antioxidant, not a peptide. Injectable administration should follow professional/product guidance.

NAD+

Reconstitution reference: 10 mL BAC water / 500 mg vial (reference)
Dose / study reference: Reference: 50–250 mg, 2–3× weekly
Cycle / context: 4–8 weeks (reference)
Research note: Coenzyme, not a peptide; evidence for many marketed wellness claims remains limited.

SLEEP OPTIMIZATION

DSIP

Reconstitution reference: 2 mL BAC water / 5 mg vial
Dose / study reference: Reference: 100–300 mcg before bedtime
Cycle / context: 4–8 weeks (reference)
Research note: Experimental peptide with limited clinical evidence.

Sermorelin

Reconstitution reference: 3 mL BAC water / 5 mg vial
Dose / study reference: Reference: 200–300 mcg daily
Cycle / context: Research/prescription context varies
Research note: GHRH analog; current regulatory/formulation status should be verified.

CJC-1295 with DAC

Reconstitution reference: 2 mL BAC water / 2 mg vial
Dose / study reference: Reference: 1–2 mg twice weekly
Cycle / context: Research reference
Research note: Investigational GHRH analog; sleep claims are not established indications.

COGNITIVE ENHANCEMENT & FOCUS

Semax

Reconstitution reference: Often supplied as nasal formulation
Dose / study reference: Reference: 200–400 mcg/day intranasal
Cycle / context: 2–4 weeks (reference)
Research note: ACTH-derived peptide used/researched in some countries; not FDA-approved in the U.S.

Selank

Reconstitution reference: Often supplied as nasal formulation
Dose / study reference: Reference: 250–750 mcg/day intranasal
Cycle / context: 2–4 weeks (reference)
Research note: Tuftsin-derived peptide used/researched in some countries; not FDA-approved in the U.S.

Cerebrolysin

Reconstitution reference: Pre-formulated ampoules
Dose / study reference: Clinical protocols vary by country/indication
Cycle / context: Medical supervision
Research note: Porcine brain-derived peptide mixture; not FDA-approved in the U.S.

Cortagen

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator marketed in some regions; high-quality human evidence is limited.

SEXUAL PERFORMANCE & LIBIDO

PT-141 / bremelanotide

Reconstitution reference: Follow approved product formulation; research vials vary
Dose / study reference: Approved product dosing is indication-specific
Cycle / context: As prescribed
Research note: Bremelanotide is FDA-approved for a specific indication in premenopausal women; compounded/research vial instructions are not equivalent.

Kisspeptin

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: No general approved self-use dose
Cycle / context: Research/clinical setting
Research note: Endogenous reproductive neuropeptide studied in reproductive endocrinology.

Melanotan II

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: No established approved human dose
Cycle / context: Experimental
Research note: Unapproved melanocortin analog.

Oxytocin

Reconstitution reference: Product-specific
Dose / study reference: Prescription dosing depends on route/indication
Cycle / context: Medical supervision
Research note: Prescription hormone; not a generic peptide self-use protocol.

ANTI-AGING & LONGEVITY

Epitalon / Epithalon

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: Reference: 5–10 mg daily
Cycle / context: 10–20 days (reference)
Research note: Experimental tetrapeptide; longevity claims are not established clinical outcomes.

FOXO4-DRI

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: No established human dose
Cycle / context: Preclinical research
Research note: Experimental senolytic peptide studied mainly in preclinical models.

Thymosin Alpha-1

Reconstitution reference: Product-specific; reference vials vary
Dose / study reference: Clinical/research regimens vary
Cycle / context: 4–12 weeks (reference)
Research note: Immune-modulating peptide approved in some countries, not FDA-approved in the U.S.

PNC-27

Reconstitution reference: 3 mL BAC water / 30 mg vial
Dose / study reference: No established human dose
Cycle / context: Preclinical/experimental
Research note: Experimental anticancer peptide; not an approved cancer treatment.

Cartalax

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Bioregulator marketed for vascular/cartilage-related research; evidence limited.

Vilon

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Livagen

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Ovagen

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Pinealon

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Prostamax

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Testagen

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Vesugen

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

AESTHETIC & COSMETIC

GHK-Cu

Reconstitution reference: 10 mL BAC water / 50–100 mg vial (reference)
Dose / study reference: Reference varies by route
Cycle / context: 4–12 weeks (reference)
Research note: Copper tripeptide with topical/cosmetic research; injectable use is not an established cosmetic standard.

SNAP-8

Reconstitution reference: Formulation-specific
Dose / study reference: Primarily discussed as a topical cosmetic ingredient
Cycle / context: Varies
Research note: Acetyl octapeptide-3 cosmetic ingredient; injectable protocols are not established.

Melanotan II

Reconstitution reference: 2 mL BAC water / 10 mg vial
Dose / study reference: No established approved human dose
Cycle / context: Experimental
Research note: Unapproved melanocortin analog; tanning does not make UV exposure safe.

IMMUNE SYSTEM SUPPORT

Thymosin Alpha-1

Reconstitution reference: Product-specific
Dose / study reference: Clinical/research regimens vary
Cycle / context: 4–12 weeks (reference)
Research note: Immune-modulating peptide; regulatory status varies by country.

VIP

Reconstitution reference: Formulation-specific
Dose / study reference: Clinical protocols vary
Cycle / context: Medical supervision
Research note: Vasoactive intestinal peptide has broad physiologic effects; CIRS use is not an FDA-approved indication.

KPV

Reconstitution reference: 3 mL BAC water / 10 mg vial
Dose / study reference: Reference: 200–500 mcg daily
Cycle / context: 4–8 weeks (reference)
Research note: α-MSH-derived tripeptide studied for anti-inflammatory signaling; investigational.

Vilon

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator; evidence limited.

Chonluten

Reconstitution reference: 2 mL BAC water / 20 mg vial
Dose / study reference: Reference: 100 mcg daily
Cycle / context: 10–20 days (reference)
Research note: Peptide bioregulator marketed for pulmonary research; evidence limited.

Goal-Specific Stack References

The submitted guide also included multi-compound “fat loss,” muscle-building, recovery, longevity, performance, aesthetic, and anti-aging stacks. Because combining investigational compounds can materially change risk and there is no validated universal protocol for these combinations, the site presents them as research topics rather than recommended dosing regimens. Individual compounds can be searched above.

Legal / educational notice: Research and educational information only. Regulatory status varies by compound and country. This material does not establish safety, efficacy, purity, or suitability for any individual.